Closed

anti-nef (aa82-91) TCR, pCDTCR1 (TCR-L075Z)

The vector of anti-nef T cell receptor (TCR) is constructed for the engineering of T cell to target HIV nef . The T cells are genetically modified through transduction with a retroviral vector expressing nef -specific T cell receptor. And the vector product was designed for the treatment of AIDS.

Details

  • Target
  • nef
  • Target Species
  • HIV
  • Epitope
  • KAAVDLSHFL
  • Format
  • Non-modified
  • HLA
  • HLA-C*0802
  • Targeting Diseases
  • AIDS
  • Vector Name
  • pCDTCR1
  • Vector Length
  • 8kb
  • Vector Type
  • Lentiviral
  • Antibody Host
  • Human

Target

  • Gene Name
  • Nef
  • Official Symbol
  • nef
  • Synonyms
  • HIV Nef; Human Immunodeficiency Viruse Nef; Human Immunodeficiency Viruse; HIV Nef protein; HIV Nef-protein
  • Introduction
  • The HIV Nef protein is a multifunctional virulence factor that perturbs intracellular membranes and
    signalling and is secreted into exosomes. While Nef-containing exosomes have a distinct proteomic
    profile, no comprehensive analysis of their miRNA cargo has been carried out. Since Nef functions as a
    viral suppressor of RNA interference and disturbs the distribution of RNA-induced silencing complex
    proteins between cells and exosomes, we hypothesized that it might also affect the export of miRNAs
    into exosomes

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry
Products

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code

Key Updates

Receive the latest news and insights to your inbox.